Sign up to save your podcasts
Or
Share Nasser Altorki, MD - Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Nasser Altorki, MD - Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right
Go online to PeerView.com/CDB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Research and clinical practice continue to build on the success achieved to date with cancer immunotherapy and to refine rational strategies to expand its benefits to more patients, including in curative-intent settings. Immunotherapy has started to radically transform the multimodal approach to treatment of resectable stage I-III NSCLC. Recently, highly positive data have emerged from the first few phase 3 trials evaluating neoadjuvant and adjuvant immunotherapies in resectable lung cancer, leading to regulatory approvals and new standards of care in these settings. What do these advances mean for thoracic surgeons, medical oncologists, pulmonologists, and other multidisciplinary specialists, and what changes in practice are needed? What challenges and unanswered questions remain? This PeerView educational activity, based on a recent live symposium, brings together top experts to discuss new, practice-changing evidence, the implications and applicability of the latest data to practice, and how to achieve better partnerships across disciplines to facilitate the incorporation of immunotherapies into new standards of care to improve outcomes and quality of life for patients with stage I-III NSCLC. Upon completion of this activity, participants should be better able to: Discuss the mechanistic and biologic rationale for using immunotherapy as a component of multimodal therapy in early-stage lung cancer and key clinical trials evaluating immunotherapies in these settings; Summarize the latest findings on surrogate endpoints, such as pathologic response criteria, to assess treatment response and evaluate the prognosis of patients with resectable lung cancer who are receiving immunotherapy; Identify patients with resectable NSCLC who are eligible for perioperative immunotherapy, considering the benefits/limitations and surgical implications based on an understanding of the latest evidence and persisting misperceptions; and Collaborate with the multidisciplinary team to integrate immunotherapy into individualized, multimodal treatment plans for eligible patients with stage I-III resectable NSCLC.
View all episodes
By PVI, PeerView Institute for Medical Education
4.1
2525 ratings
Go online to PeerView.com/CDB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Research and clinical practice continue to build on the success achieved to date with cancer immunotherapy and to refine rational strategies to expand its benefits to more patients, including in curative-intent settings. Immunotherapy has started to radically transform the multimodal approach to treatment of resectable stage I-III NSCLC. Recently, highly positive data have emerged from the first few phase 3 trials evaluating neoadjuvant and adjuvant immunotherapies in resectable lung cancer, leading to regulatory approvals and new standards of care in these settings. What do these advances mean for thoracic surgeons, medical oncologists, pulmonologists, and other multidisciplinary specialists, and what changes in practice are needed? What challenges and unanswered questions remain? This PeerView educational activity, based on a recent live symposium, brings together top experts to discuss new, practice-changing evidence, the implications and applicability of the latest data to practice, and how to achieve better partnerships across disciplines to facilitate the incorporation of immunotherapies into new standards of care to improve outcomes and quality of life for patients with stage I-III NSCLC. Upon completion of this activity, participants should be better able to: Discuss the mechanistic and biologic rationale for using immunotherapy as a component of multimodal therapy in early-stage lung cancer and key clinical trials evaluating immunotherapies in these settings; Summarize the latest findings on surrogate endpoints, such as pathologic response criteria, to assess treatment response and evaluate the prognosis of patients with resectable lung cancer who are receiving immunotherapy; Identify patients with resectable NSCLC who are eligible for perioperative immunotherapy, considering the benefits/limitations and surgical implications based on an understanding of the latest evidence and persisting misperceptions; and Collaborate with the multidisciplinary team to integrate immunotherapy into individualized, multimodal treatment plans for eligible patients with stage I-III resectable NSCLC.
More shows like PeerView Internal Medicine CME/CNE/CPE Audio Podcast
View all
Hidden Brain
43,570 Listeners
JAMA Editors' Summary
136 Listeners
NEJM This Week
320 Listeners
AFP: American Family Physician Podcast
700 Listeners
JAMA Clinical Reviews
496 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
10 Listeners
Science Quickly
1,384 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
10 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
4 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
4 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
2 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
4 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
Mayo Clinic Talks
288 Listeners
Frankly Speaking About Family Medicine
262 Listeners
The Curbsiders Internal Medicine Podcast
3,342 Listeners
Core IM | Internal Medicine Podcast
1,155 Listeners
Annals On Call Podcast
194 Listeners
JAMA Medical News
85 Listeners
The Clinical Problem Solvers
511 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
365 Listeners
Cardionerds: A Cardiology Podcast
432 Listeners